Giovanni Rizzo
Intercept Pharmaceuticals
29 Papers
174 Citations
Giovanni Rizzo is an academic researcher from Intercept Pharmaceuticals. The author has contributed to research in topics: Farnesoid X receptor & Receptor. The author has an hindex of 24, co-authored 27 publications. Previous affiliations of Giovanni Rizzo include Research Triangle Park & Istituto Superiore di Sanità.
Chat about Author
Papers
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas,Antimo Gioiello,Lilia G. Noriega,Lilia G. Noriega,Axelle Strehle,Julien Oury,Giovanni Rizzo,Antonio Macchiarulo,Hiroyasu Yamamoto,Hiroyasu Yamamoto,Chikage Mataki,Chikage Mataki,Mark Pruzanski,Roberto Pellicciari,Johan Auwerx,Johan Auwerx,Kristina Schoonjans,Kristina Schoonjans +17 more
TL;DR: It is shown here that TGR5 signaling induces intestinal glucagon-like peptide-1 (GLP-1) release, leading to improved liver and pancreatic function and enhanced glucose tolerance in obese mice, and suggested that pharmacological targeting of T GR5 may constitute a promising incretin-based strategy for the treatment of diabesity and associated metabolic disorders.
1.7K
The third gas: H2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis
Stefano Fiorucci,Elisabetta Antonelli,Andrea Mencarelli,Stefano Orlandi,Barbara Renga,Giovanni Rizzo,Eleonora Distrutti,Vijay H. Shah,Antonio Morelli +8 more
TL;DR: In conclusion, CSE‐derived H2S is involved in the maintenance of portal venous pressure and the reduction of CSE expression in the liver with cirrhosis contributes to the development of increased intrahepatic resistance and portal hypertension.
551
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading.
Thijs W.H. Pols,Mitsunori Nomura,Taoufiq Harach,Giuseppe Lo Sasso,Maaike H. Oosterveer,Charles Thomas,Giovanni Rizzo,Antimo Gioiello,Luciano Adorini,Roberto Pellicciari,Johan Auwerx,Kristina Schoonjans +11 more
TL;DR: It is demonstrated that activation of TGR5 in macrophages by 6α-ethyl-23(S)-methylcholic acid (6-EMCA, INT-777), a semisynthetic BA, inhibits proinflammatory cytokine production, an effect mediated by T GR5-induced cAMP signaling and subsequent NF-κB inhibition.
535
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis
Stefano Fiorucci,Elisabetta Antonelli,Giovanni Rizzo,Barbara Renga,Andrea Mencarelli,Luisa Riccardi,Stefano Orlandi,Roberto Pellicciari,Antonio Morelli +8 more
TL;DR: It is established that FXR ligands might represent a novel therapeutic option to treat liver fibrosis and that SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by thrombin.
480
A role for proteinase-activated receptor-1 in inflammatory bowel diseases
Nathalie Vergnolle,Laurie Cellars,Andrea Mencarelli,Giovanni Rizzo,Sunita Swaminathan,Paul L. Beck,Martin Steinhoff,Patricia Andrade-Gordon,Nigel W. Bunnett,Morley D. Hollenberg,John L. Wallace,Giuseppe Cirino,Stefano Fiorucci +12 more
TL;DR: The results imply an important role for PAR1 in the pathogenesis of experimental colitis, supporting the notion that PAR1 inhibition may be beneficial in the context of IBD and possibly in other chronic intestinal inflammatory disorders.